Media

Lupin Receives Tentative Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC)

Lupin Receives Approval from U.S. FDA for Prednisolone Acetate Ophthalmic Suspension USP

Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets

Lupin Receives Tentative Approval from U.S. FDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)

Lupin’s Alliance Partner ForDoz Receives U.S. FDA Approval for Doxorubicin Hydrochloride Liposome Injection

Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets

Lupin Receives EIR from U.S. FDA for its Dabhasa Facility

Lupin Receives Approval from U.S. FDA for Topiramate Extended-Release Capsules

Lupin Receives Tentative Approval from U.S. FDA for Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release Tablets